文献速递生殖医学

胚胎植入前遗传学诊断联合HLA配型的临床效用:一项欧洲人类生殖与胚胎学会多中心协作研究

The clinical utility of PGD with HLA matching: a collaborative multi-centre ESHRE study.
PubMed 文献 · Hum Reprod · 2018-01-01

该回顾性多中心队列研究纳入14个中心2001年8月至2015年9月间的704个HLA-PGD周期,涉及364对夫妇。诊断效能为78.5%,低于已发表的HLA-PGD方案及欧洲人类生殖与胚胎学会报告的通用PGD数据(分别为94.1%和92.6%)。由于对辅助生殖/胚胎植入前遗传学诊断及造血干细胞移植结局随访不足,临床效能难以评估。

要点

  • 704个周期中,每对夫妇平均1.93个周期,平均取卵13.9枚/周期,分析胚胎7.9枚/周期。
  • 每移植周期妊娠率41.3%,每起始周期23.3%;每移植周期活产率34.3%,每起始周期19.3%。
  • 57例造血干细胞移植中,64.9%采用脐带血联合骨髓移植,77.3%无并发症。

核心结论

  • HLA-PGD方案的诊断效能低于已发表方案及欧洲人类生殖与胚胎学会通用PGD报告值(78.5% vs 94.1%和92.6%)。
  • 由于对辅助生殖/胚胎植入前遗传学诊断及造血干细胞移植结局随访不足,临床效能难以评估。

研究设计与样本

  • 回顾性多中心队列研究,2014年4月邀请32个有HLA-PGD活动记录的中心参与,2015年2月至9月共14个中心通过定制安全数据库提交数据。
  • 纳入2001年8月至2015年9月间的716个周期,质量评估排除12个周期,最终分析704个周期,来自364对夫妇。

主要发现

  • 平均母亲年龄33.5岁,81.3%的夫妇要求HLA配型同时排除单基因病(其中58.6%为β-地中海贫血)。
  • 92.5%的夫妇双方生育力正常,平均每对夫妇1.93个HLA-PGD周期;共取卵9751枚(13.9枚/周期),分析胚胎5532枚(7.9枚/周期)。
  • 94.9%的周期使用新鲜卵母细胞,85.3%采用第3天胚胎活检,97.5%的周期基因分型方法仅涉及聚合酶链反应。
  • 4343枚胚胎被诊断(占分析胚胎的78.5%),677枚遗传学合适(占仅HLA分析胚胎的15.4%,占HLA联合单基因病排除分析胚胎的11.6%)。
  • 364对夫妇中56.6%获得胚胎移植,382个周期共移植598枚胚胎,导致164例HCG阳性妊娠(每移植周期妊娠率41.3%,每起始周期23.3%),113对夫妇分娩136个婴儿(每移植周期活产率34.3%,每起始周期19.3%)。

关键数值与推荐

  • 诊断效能(诊断胚胎占分析胚胎的比例)为78.5%,低于已发表HLA-PGD方案的94.1%和欧洲人类生殖与胚胎学会报告的通用PGD的92.6%。
  • 影响HLA-PGD整体成功的因素包括:接受治疗周期的母亲年龄、每周期采集的卵母细胞数和遗传概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 并非所有具有HLA-PGD经验的中心都参与了研究,可能限制研究结果。
  • 在线数据库完成情况可能存在报告偏倚。
  • 研究基于回顾性数据收集,且各中心在辅助生殖技术、胚胎学和遗传诊断方面的实践和策略存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Has PGD-HLA been successful relative to diagnostic and clinical efficacy? SUMMARY ANSWER: The diagnostic efficacy of PGD-HLA protocols was found lower in this study in comparison to published PGD-HLA protocols and to that reported for general PGD by ESHRE (78.5 vs 94.1% and vs 92.6%, respectively), while the clinical efficacy has proven very difficult to assess due to inadequate follow-up of both the ART/PGD and HSCT procedure outcomes. WHAT IS KNOWN ALREADY: The first clinical cases for PGD-HLA were reported in 2001. It is now a well-established procedure, with an increasing number of cycles performed every year. However, PGD-HLA is still offered by relatively few PGD centres, the currently available data is fragmented and most reports on PGD-HLA applications are limited in number and scope. Published systematic details on methodology, diagnostic results, overall ART success and haematopoietic stem cell transplantation (HSCT) outcomes are limited, precluding an evaluation of the true clinical utility of PGD-HLA cycles. STUDY DESIGN, SIZE, DURATION: This retrospective multi-centre cohort study aimed to investigate the diagnostic and clinical efficacy of the PGD-HLA procedure and the aspects of PGD-HLA cycles influencing positive outcomes: birth of genetically suitable donor-baby (or babies) and HSCT. In April 2014, 32 PGD centres (Consortium members and non-members) with published/known PGD-HLA activity were invited to participate. Between February and September 2015, 14 centres submitted their data, through a custom-designed secure database, with unique login access for each centre. Data parameters covered all aspects of PGD-HLA cycles (ART, embryology and genetic diagnosis), donor-babies born and HSCT. PARTICIPANTS/MATERIALS, SETTING, METHODS: From 716 cycles submitted by 14 centres (performed between August 2001 and September 2015), the quality evaluation excluded 12 cycles, leaving 704, from 364 couples. The online database, based on REDCap, a free, secure, web-based data-capture application, was customized by Centre for Clinical Epidemiology and Outcomes Research (CLEO), Athens. Continuous variables are presented using mean, standard deviation, median and interquartile range, and categorical variables are presented as absolute and relative frequencies. MAIN RESULTS AND THE ROLE OF CHANCE: The data included 704 HLA-PGD cycles. Mean maternal age was 33.5 years. Most couples (81.3%) requested HLA-typing with concurrent exclusion of a single monogenic disease (58.6% for beta-thalassaemia). In 92.5% couples, both partners were fertile, with an average 1.93 HLA-PGD cycles/couple. Overall, 9751 oocytes were retrieved (13.9/cycle) and 5532 embryos were analysed (7.9/cycle). Most cycles involved fresh oocytes (94.9%) and Day 3 embryo biopsy (85.3%). In 97.5% of cycles, the genotyping method involved PCR only. Of 4343 embryos diagnosed (78.5% of analysed embryos), 677 were genetically suitable (15.4% of those analysed for HLA alone, 11.6% of those analysed for HLA with exclusion of monogenic disease). Of the 364 couples, 56.6% achieved an embryo transfer (ET) and 598 embryos were transferred in 382 cycles, leading to 164 HCG-positive pregnancies (pregnancy rate/ET 41.3%, pregnancy rate/initiated cycle 23.3%) and 136 babies born (live birth rate/ET 34.3%, live birth rate/initiated cycle 19.3%) to 113 couples. Data analysis identified the following limitations to the overall success of the HLA-PGD procedure: the age of the mother undergoing the treatment cycle, the number of oocytes collected per cycle and genetic chance. HSCT was reported for 57 cases, of which 64.9% involved combined umbilical cord-blood and bone marrow transplantation from the HLA-identical sibling donor; 77.3% of transplants reported no complications. LIMITATIONS REASONS FOR CAUTION: The findings of the study may be limited as not all PGD centres with PGD-HLA experience participated. Reporting bias on completion of the online database may be another potential limitation. Furthermore, the study is based on retrospective data collection from centres with variable practices and strategies for ART, embryology and genetic diagnosis. WIDER IMPLICATIONS OF THE FINDINGS: This is the first multi-centre study evaluating the clinical utility of PGD-HLA, indicating variations in practice and outcomes throughout 15 years and between centres. The study highlights parameters important for positive outcomes and provides important information for both scientists and couples interested in initiating a cycle. Above all, the study underlines the need for better collaboration between all specialists involved in the ART-PGD/HLA procedure, as well as the need for comprehensive and prospective long-term data collection, and encourages all specialists to aim to properly evaluate and follow-up all procedures, with the ultimate aim to promote best practice and encourage patient informed decision making. STUDY FUNDING/COMPETING INTEREST(S): The study wishes to acknowledge ESHRE for funding the customization of the REDCap database. There are no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kakourou G, Kahraman S, Ekmekci GC, et al. The clinical utility of PGD with HLA matching: a collaborative multi-centre ESHRE study. Hum Reprod. 2018. PMID: 29432583. doi:10.1093/humrep/dex384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。